HROW
Harrow·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Strong Buy"
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About HROW
Harrow, Inc.
An eyecare pharmaceutical company that developing innovative ophthalmic prescription therapies
1A Burton Hills Blvd., Suite 200, Nashville, TN 37215
--
Harrow, Inc., was incorporated in Delaware in January 2006. The company is a leading eye care pharmaceutical company dedicated to discovering, developing and commercializing innovative ophthalmic pharmaceutical products for the US market. The company owns the commercial rights to a large portfolio of branded ophthalmic medicines sold under the Harrow name and also operates ImprimisRX, a prominent ophthalmology-focused drug compounding business. The company's goal is to make its comprehensive prescription and over-the-counter products accessible and affordable to support eye care professionals across the United States.
Company Financials
EPS
HROW has released its 2025 Q3 earnings. EPS was reported at 0.33, versus the expected 0.24, beating expectations. The chart below visualizes how HROW has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
HROW has released its 2025 Q3 earnings report, with revenue of 71.64M, reflecting a YoY change of 45.44%, and net profit of 1.02M, showing a YoY change of 124.17%. The Sankey diagram below clearly presents HROW's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
